

Title (en)

COMPOSITIONS AND METHODS FOR TCR REPROGRAMMING USING FUSION PROTEINS

Title (de)

ZUSAMMENSETZUNGEN UND VERFAHREN ZUR TCR-REPROGRAMMIERUNG MITHILFE VON FUSIONSPROTEINEN

Title (fr)

COMPOSITIONS ET PROCÉDÉS DE REPROGRAMMATION DE TCR À L'AIDE DE PROTÉINES DE FUSION

Publication

EP 4028033 A4 20231004 (EN)

Application

EP 20862242 A 20200911

Priority

- US 201962899563 P 20190912
- US 202062971682 P 20200207
- US 2020050503 W 20200911

Abstract (en)

[origin: WO2021050948A1] Provided herein are recombinant nucleic acids encoding T cell receptor (TCR) fusion proteins (TFPs) and a TCR constant domain, modified T cells expressing the encoded molecules, and methods of use thereof for the treatment of diseases, including cancer. Described herein are modified T cells comprising fusion proteins of TCR subunits, including CD3 epsilon, CD3gamma, CD3 delta, TCR gamma, TCR delta, TCR alpha and TCR beta chains with binding domains specific for cell surface antigens that have the potential to overcome limitations of existing approaches.

IPC 8 full level

A61K 35/17 (2015.01); **A61K 39/00** (2006.01); **A61P 35/00** (2006.01); **C07K 14/725** (2006.01); **C12N 5/0783** (2010.01); **C12N 15/113** (2010.01); **C12N 15/62** (2006.01); **C12N 15/90** (2006.01)

CPC (source: EP IL KR)

A61K 39/4611 (2023.05 - EP IL KR); **A61K 39/4632** (2023.05 - EP IL KR); **A61K 39/464412** (2023.05 - EP IL KR); **A61P 35/00** (2018.01 - EP IL KR); **C07K 14/7051** (2013.01 - EP IL KR); **C07K 16/2803** (2013.01 - KR); **C12N 5/0636** (2013.01 - EP IL KR); **C12N 15/1138** (2013.01 - EP IL); **C12N 15/62** (2013.01 - KR); **C12N 15/86** (2013.01 - KR); **C12N 15/907** (2013.01 - EP IL); **A61K 2239/26** (2023.05 - EP IL KR); **A61K 2239/48** (2023.05 - EP IL KR); **C07K 2319/03** (2013.01 - EP IL KR); **C07K 2319/50** (2013.01 - EP); **C12N 2310/20** (2017.05 - EP IL KR); **C12N 2510/00** (2013.01 - EP IL KR); **C12N 2740/15041** (2013.01 - EP)

Citation (search report)

- [I] WO 2019133443 A1 20190704 - JANUX THERAPEUTICS INC [US]
- [I] WO 2017158116 A1 20170921 - IMMATICS BIOTECHNOLOGIES GMBH [DE]
- [A] WO 2019118508 A1 20190620 - UNIV PENNSYLVANIA [US]
- [A] ANNA CAPSOMIDIS ET AL: "Chimeric Antigen Receptor-Engineered Human Gamma Delta T Cells: Enhanced Cytotoxicity with Retention of Cross Presentation", MOLECULAR THERAPY, vol. 26, no. 2, 1 February 2018 (2018-02-01), US, pages 354 - 365, XP055590617, ISSN: 1525-0016, DOI: 10.1016/j.ymthe.2017.12.001
- See also references of WO 2021050948A1

Designated contracting state (EPC)

AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DOCDB simple family (publication)

WO 2021050948 A1 20210318; AU 2020344628 A1 20220407; BR 112022004458 A2 20220531; CA 3154287 A1 20210318; CN 114828862 A 20220729; EP 4028033 A1 20220720; EP 4028033 A4 20231004; IL 291236 A 20220501; JP 2022548866 A 20221122; KR 20220078607 A 20220610; MX 2022002984 A 20220616

DOCDB simple family (application)

US 2020050503 W 20200911; AU 2020344628 A 20200911; BR 112022004458 A 20200911; CA 3154287 A 20200911; CN 202080079086 A 20200911; EP 20862242 A 20200911; IL 29123622 A 20220309; JP 2022516320 A 20200911; KR 20227012166 A 20200911; MX 2022002984 A 20200911